Compare BTM & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTM | NKTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 133.5M |
| IPO Year | N/A | 2020 |
| Metric | BTM | NKTX |
|---|---|---|
| Price | $1.33 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.25 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.5M | 650.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $635,643,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.24 | ★ N/A |
| Revenue Growth | ★ 8.61 | N/A |
| 52 Week Low | $0.93 | $1.31 |
| 52 Week High | $6.88 | $2.74 |
| Indicator | BTM | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 45.33 |
| Support Level | $1.29 | $1.81 |
| Resistance Level | $1.69 | $1.90 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 8.75 | 52.50 |
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.